Cyclopentolate
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Cyclopentolate: From Ophthalmic Mydriasis to Cauda Equina Syndrome
One-Sentence Summary
Cyclopentolate is a short-acting anticholinergic (antimuscarinic) agent used topically in ophthalmology to produce mydriasis and cycloplegia. The TxGNN model predicts a possible link to Cauda Equina Syndrome, but this is supported by 0 clinical trials and 0 publications, and the model’s own mechanistic assessment finds no plausible pharmacological pathway between the two conditions.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ophthalmic mydriasis/cycloplegia (not formally recorded in this evidence pack; the drug is not currently UK-marketed) |
| Predicted New Indication | Cauda Equina Syndrome |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for cyclopentolate has not been confirmed in this evidence pack (flagged as a High-severity data gap requiring DrugBank API verification). Based on known pharmacology, cyclopentolate is a short-acting antimuscarinic used exclusively as a topical ophthalmic agent to induce pupil dilation and paralysis of accommodation ahead of eye examinations or procedures.
Cauda equina syndrome, by contrast, is a surgical emergency caused by compression of the lumbosacral nerve roots, requiring urgent decompressive surgery. There is no established pharmacological mechanism by which a topical antimuscarinic eye drop would treat or modify the course of this condition.
The model’s own rationale is explicit on this point: the high TxGNN score most likely reflects graph-level co-occurrence or proximity between nodes in the knowledge graph, rather than a genuine causal or mechanistic relationship. No clinical trials or literature evidence exist to support this candidate, and no route-of-administration or dosing pathway has been established for systemic or off-label use in this context.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Cyclopentolate does not currently hold any UK marketing authorisation recorded in this evidence pack (0 licenses on file; market status: not marketed). No product, dosage form, or approved-indication data is therefore available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: UK product labelling/warnings and contraindication data for cyclopentolate were not available in this evidence pack — this is flagged as a Blocking data gap that must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted association between cyclopentolate and cauda equina syndrome lacks any supporting clinical trial or literature evidence, and the repurposing rationale itself concludes there is no credible pharmacological mechanism linking a topical ophthalmic antimuscarinic to a surgical nerve-compression emergency. The high TxGNN score appears to reflect knowledge-graph proximity rather than causal relevance, and no UK regulatory or safety data are currently available to support further evaluation.
To proceed, the following is needed:
- Confirmed mechanism of action data from DrugBank (DG002)
- UK/SmPC warnings, contraindications, and drug interaction data (DG001 — currently blocking any safety evaluation)
- Independent pharmacological or preclinical rationale specifically connecting cyclopentolate to neurological/nerve-root pathology, if this candidate is to be pursued further
- As an alternative research direction, the model’s second- and third-ranked predictions (neurogenic bladder and irritable bowel syndrome) carry somewhat stronger class-level rationale, as antimuscarinics are an established drug class for both conditions — though these too remain at evidence level L5 with no supporting trials or literature, and are appropriately flagged as open research questions rather than actionable candidates at this stage.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.